**Core Concept:** Pembrolizumab is a monoclonal antibody that targets PD-1 (programmed cell death protein 1), which is an immune checkpoint protein that plays a crucial role in regulating the immune system. Its inhibition allows the immune system to recognize and attack cancer cells more effectively.

**Why the Correct Answer is Right:** Pembrolizumab is used for the treatment of several types of cancer, including advanced melanoma, non-small cell lung cancer, head and neck cancer, and other solid tumors. Its mechanism of action involves blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This leads to the activation of cytotoxic T cells, which can directly kill cancer cells and stimulate an immune response against tumor cells.

**Why Each Wrong Option is Incorrect:**

A. Melanoma (Option A) is a type of skin cancer, not a condition treated with pembrolizumab.
B. Multiple myeloma (Option B) is a plasma cell disorder, not a condition treated by pembrolizumab.
C. Chronic lymphocytic leukemia (Option C) is a type of leukemia, not a condition treated by pembrolizumab.
D. Pembrolizumab is a monoclonal antibody, not a treatment for cancer.

**Clinical Pearl:** The understanding of immune checkpoint proteins like PD-1 and their role in cancer immunotherapy has revolutionized cancer treatment, leading to the development of drugs like pembrolizumab that can enhance the immune system's ability to recognize and eliminate cancer cells. This has significantly improved the prognosis and overall survival of patients with advanced cancers.